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Abstract
Background/Objectives
Inflammation and oxidative stress are central in many disease states. The major anti-oxida-
tive enzymes contain selenium. The selenium intake in Europe is low, and supplementation
with selenium and coenzyme Q10, important anti-oxidants, was evaluated in a previous
study. The aim of this study was to evaluate response on the inflammatory biomarkers C-
reactive protein, and sP-selectin, and their possible impact on cardiovascular mortality.
Subjects/Methods
437 elderly individuals were included in the study. Clinical examination, echocardiography,
electrocardiography and blood samples were drawn. The intervention time was 48 months,
and median follow-up was 5.2 years. The effects on inflammation/atherosclerosis were
evaluated through analyses of CRP and sP-selectin. Evaluations of the effect of the inter-
vention was performed using repeated measures of variance. All mortality was registered,
and endpoints of mortality were assessed by Kaplan-Meier plots.
Results
The placebo group showed a CRP level of 4.8 ng/mL at the start, and 5.1 ng/mL at the study
end. The active supplementation group showed a CRP level of 4.1 ng/mL at the start, and 2.1
ng/mL at the study end. SP-selectin exhibited a level of 56.6 mg/mL at the start in the placebo
group and 72.3 mg/mL at the study end, and in the active group the corresponding figures
were 55.9 mg/mL and 58.0 mg/mL. A significantly smaller increase was demonstrated
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through repeated measurements of the two biomarkers in those on active supplementation.
Active supplementation showed an effect on the CRP and sP-selectin levels, irrespective of
the biomarker levels. Reduced cardiovascular mortality was demonstrated in both those with
high and low levels of CRP and sP-selectin in the active supplementation group.
Conclusion
CRP and sP-selectin showed significant changes reflecting effects on inflammation and ath-
erosclerosis in those given selenium and coenzyme Q10 combined. A reduced cardiovascu-
lar mortality could be demonstrated in the active group, irrespective of biomarker level. This
result should be regarded as hypothesis-generating, and it is hoped it will stimulate more
research in the area.
Introduction
Inflammation is part of the atherosclerotic process in the body[1], but also in other processes,
including different disease states such as e.g. cardiometabolic syndrome, acute coronary syn-
dromes [2, 3], heart failure with preserved ejection fraction [4, 5] as well as heart failure with
reduced ejection fraction [6, 7] and also in aortic stenosis [8] and rheumatoid inflammations that
may predispose a patient to cardiovascular disease. Aging itself is also associated with an increased
inflammatory response [9]. An increased inflammatory response in disease states or in the elderly
can be a marker of disease progression as well as an indicator of a poorer prognosis [10]
Inflammation and atherosclerosis are interrelated conditions that are also associated with
increased oxidative stress in the body [11]. The selenium-containing enzymes glutathione per-
oxidase, selenoprotein P and thioredoxin reductase are some of the major contenders in the
defence against oxidative stress in the body [12]. An association between ischemic heart disease
and intake of selenium has been discussed for a long time, [13, 14]. However, there are also
conflicting reports on the effectiveness of intervention with selenium in cardiovascular disease
[15–19].
The intake of selenium is generally low in Europe, and has been estimated to be around
40 μg/day [20]. The required intake of selenium in order to obtain optimal function of the
intracellular enzyme glutathione peroxidase, and the extracellular protector selenoprotein P
has been discussed, and Xia et al. reported a needed intake of 75 μg/day of selenium for adult
Caucasians [21]. During conditions of increased oxidative stress and inflammation there is an
increased need for intake of selenium [22]. A possible association between cardiovascular dis-
ease and death and intake of selenium has been discussed in the literature. Salonen et al.
reported a 2.9 fold increase in cardiovascular mortality in those with a low selenium intake
[14]. However, conflicting reports regarding the effectiveness of intervention with selenium on
cardiovascular disease have also been published [15–19].
Coenzyme Q10 (ubiquinone) is present in all living cells in the body where it is an important
antioxidant, but is also active in the mitochondrial respiratory chain. However, the endogenous
production of coenzyme Q10 declines after the age of 20, and in the myocardial cells it is
reduced to about half at the age of 80 years [23]. As observed by Xia et al. there is an important
interrelationship between selenium and coenzyme Q10, as selenium (selenocystein) is needed
for the reduction of ubiquinone to ubiquinol, the active form of coenzyme Q10 [24, 25]. This
interrelationship might explain the conflicting results in studies performed in areas with low
selenium intake, where just one of the substances has been supplemented.
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There is sparse information of the supplementation of selenium and coenzyme Q10 com-
bined. However, Kuklinski, in a small study, reported lower mortality, a decreased plasma level
of the biomarker N-terminal fragment of proBrain Natriuretic Peptide (NT-proBNP), and
increased cardiac function according to echocardiography in patients with myocardial infarc-
tion who received supplementation with selenium and coenzyme Q10 in combination. We have
recently presented data from a prospective double-blind, placebo controlled study of elderly
Swedish healthy individuals, given dietary supplementation of either selenium and coenzyme
Q10 or placebo during four years of intervention [26]. The result was a reduction of cardiovas-
cular mortality, increased cardiovascular function as seen in echocardiography, and a smaller
increase in NT-proBNP as a result of the combined intervention.
The rationale for the present analysis is that selenium and coenzyme Q10 are two major con-
tenders in the human oxidative defence system [12, 27–29]; thus, a possible contributable
mechanism to the positive results might be a decreased inflammatory response by the dietary
supplementation of selenium and coenzyme Q10.
One of the most commonly used biomarkers for inflammatory response in clinical practice
is C-reactive protein (CRP). CRP is an acute phase reactant and a general marker of systemic
inflammation, but also a well-known biomarker for cardiovascular risk[30]. sP-selectin
(CD62P) is a cell adhesion molecule expressed on activated endothelial cells and involved in
their leukocyte attachment during inflammation [31]. The predominant part of sP-selectin
found in plasma originates from activated platelets, and is a biomarker for atherosclerosis.
sP-selectin has also been reported to give reliable prognostic information regarding the athero-
thrombotic process and cardiovascular risk [32, 33].
The aim of the present study was to evaluate the effect of selenium and coenzyme Q10 on
the inflammatory response as reflected by CRP and sP-selectin. A second aim was to determine
whether selenium and coenzyme Q10 had an impact on the association between inflammation
and mortality.
Methods
Study population
This is a secondary analysis of a prospective randomized double-blind placebo-controlled trial
in an elderly community population of 443 individuals with an age between 70–88 years that
has been previously reported [26, 34]. The present evaluation of sP-selectin and CRP, is a post
hoc analysis, whereas the evaluation the effect of the intervention on inflammation was
prespecified.
The first participant was included in January 2003, and the last participant concluded the
study in February 2010. All participants received the intervention for 48 months during which
they were re-examined every six months. During the study, all mortality was registered. In the
study, 221 individuals received active supplementation of 200 μg/day organic selenium (Sele-
noPrecise1, Pharma Nord, Denmark), plus 200 mg/day of coenzyme Q10 (Bio-Quinon
1,
Pharma Nord, Denmark), and 222 individuals received a placebo. At inclusion all participants
went through a clinical examination, new patient records were obtained, the New York Heart
Association functional class was assessed, and an ECG and Doppler-echocardiography was
performed. Informed consent was obtained from each patient. The study was approved by the
Regional Ethical Committee and conforms to the ethical guidelines of the 1975 Declaration of
Helsinki. (The Medical Product Agency declined to review the study protocol since the study
was not considered a trial of a medication for a certain disease but rather one of food supple-
ment commodities that are commercially available). This study was registered at Clinicaltrials.
gov, and has the identifier NCT01443780.
sP-selectin and CRP Reduced by Selenium and CoenzymeQ10
PLOSONE | DOI:10.1371/journal.pone.0137680 September 16, 2015 3 / 16
Blood samples
Blood samples were collected while the participants were resting in supine position. Pre-chilled,
EDTA-vials were used. The vials were centrifuged at 3000g, +4°C, and were then frozen at
-70°C. No sample was thawed more than once.
sP-selectin
Soluble sP-selectin (sCD62P) was analysed utilizing an ELISA from R&D (Abingdon, UK).
The intra-assay coefficient of variation (CV) was about 5% and the inter-assay CV about 9%.
C-reactive protein
hs-CRP was analysed on an Advia 1800 instrument (Siemens Healthcare Diagnostics, Stock-
holm, Sweden) using a latex-enhanced immunochemistry method with reagents from the same
company. The detection limit was 0.12 mg/L. The total CV was 1.1% at 13.3 mg/L and 2.9% at
0.99 mg/L.
Statistics
Descriptive data are presented as percentages or mean ± SD. The Student’s unpaired two-sided
T-test was used for continuous variables. Kaplan-Meier analyses and plots of cardiovascular
mortality for the period of up to 5.2 years were made separately for CRP and sP-selectin, each
divided in two at their median levels. Censored participants were those still living at the end of
the study, or who had died for reasons other than cardiovascular disease. Completed partici-
pants were those who had died due to cardiovascular disease. Evaluating the P-values between
the two groups of mortality at 1900 days was based on lifetable analyses using cumulative pro-
portional surviving, and standard error of cumulated survivals to obtain a z-value. Evaluation
of the effects of treatment were based on the group mean, but where the values of the individual
participant were identified during the three different measured time points using a repeated
measures of variance analysis. P-values< 0.05 were considered significant, based on a two-
sided evaluation. All data were analysed using standard software (Statistica v. 12.0, Statsoft Inc,
Tulsa, OK, USA.).
Results
The baseline characteristics of the study population are presented in Table 1, and a CONSORT
flow chart of the study is presented in Fig 1.
In the population, 437 individuals were evaluated as 6 participants of the 443 did not deliver
blood samples for analyses of sP-selectin. Almost equal numbers of males versus females were
found (222 males versus 215 females). The two groups (active treatment versus placebo) were
well balanced at the start except regarding treatment with ACE-inhibitors, regarding which a
significantly greater part were on treatment in the placebo group (14.8% versus 24.0%;
P = 0.02).
In the placebo group the mean concentration of CRP at study start was 4.8 ng/mL, whereas
the mean concentration at study end was 5.1 ng/mL (P = 0.91) (Table 2).
However, in the active treatment group the mean concentration of CRP at study start was
4.1 ng/mL and the concentration at study end was 2.1 ng/mL (t = -1.75; P = 0.08). Evaluating
the soluble part of sP-selectin showed a concentration in the placebo group of 56.6 mg/mL at
study start and a concentration of 72.3 mg/mL at study end (t = 4.39; P<0.0001). In the active
treatment group a concentration of sP-selectin at study start of 55.9 mg/mL was found, and a
concentration of 58.0 mg/mL at study end (t = 0.03; P = 0.97). Thus, a significant difference in
sP-selectin and CRP Reduced by Selenium and CoenzymeQ10
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sP-selectin concentration between the two groups during the intervention of 48 months could
be seen, and a trend against difference comparing the concentration of CRP between the two
groups.
However, to evaluate a possible treatment effect a repeated measures of variance was per-
formed. The model which included the two groups (active and placebo) and the measured lev-
els at three different time points (baseline, 18 and 48 months) showed a significant treatment
effect on the CRP level (F = 8.67; P = 0.004), indicating that a significant difference between
active intervention and placebo could be found. Evaluation of the interaction revealed a signifi-
cant interaction (F = 4.73; P = 0.009) indicating that the obtained treatment effect was not
based on difference in CRP level at start, but to a significantly reduced level of CRP due to the
intervention (Fig 2).
Performing the same procedure on the sP-selectin level showed a significant treatment effect
(F = 6.52; P = 0.01), and a significant interaction (F = 7.08; P = 0.0009). Thus a significant treat-
ment effect as seen on the sP-selectin level (Fig 3).
Table 1. Baseline characteristics of the study population receiving intervention of a dietary supple-
mentation of selenium and coenzymeQ10 combined during 4 years.
Active Placebo p-value
N 216 221
Age years mean (SD) 76.9 (3.5) 77.3 (3.4) 0.35
Males/Females n 112/104 110/111
History
Smokers (present) n (%) 20 (9.3) 20 (9.0) 0.94
Diabetes n (%) 46 (21.3) 48 (21.7) 0.91
Hypertension n (%) 155 (71.8) 168 (76.0) 0.31
IHD n (%) 45 (20.8) 52 (23.5) 0.50
NYHA class I n (%) 117 (54.2) 107 (48.4) 0.23
NYHA class II n (%) 58 (26.9) 64 (29.0) 0.62
NYHA class III n (%) 40 (18.5) 47 (21.3) 0.47
NYHA class IV n (%) 0 0
Medications
ACEI n (%) 32 (14.8) 53 (24.0) 0.02
ARB n (%) 10 (4.6) 13 (5.9) 0.56
Beta blockers n (%) 75 (34.7) 72 (32.6) 0.64
Digitalis n (%) 10 (4.6) 11 (5.0) 0.87
Diuretics n (%) 68 (31.5) 88 (39.8) 0.07
Statins n (%) 42 (19.4) 50 (22.6) 0.41
Examinations
EF<40% n (%) 14 (6.5) 17 (7.7) 0.65
NT-proBNP ng/L mean (IQR) 537 (398) 516 (330) 0.86
sP-Selectin mg/mL mean (IQR) 55.9 (27.7) 56.6 (31.4) 0.75
CRP mg/mL mean (IQR) 4.0 (3.6) 4.9 (4.0) 0.45
Note: ACEI: ACE- inhibitors; ARB; Angiotension receptor blockers; EF: Ejection fraction; IHD; Ischemic
heart disease; IQR: Inter quartile range; NT-proBNP: N-terminal fragment of proBNP; NYHA: New York
Heart Association functional class; SD: Standard Deviation.
doi:10.1371/journal.pone.0137680.t001
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Fig 1. CONSORT diagram illustrating the design of the study.
doi:10.1371/journal.pone.0137680.g001
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Association between inflammation and cardiovascular mortality
Of those having a CRP or sP-selectin concentration above or below the median value the distri-
bution of cardiovascular death was examined as shown in Table 3.
The extent of cardiovascular mortality in the active treatment group was about half of that
in the placebo group, even though the size of the samples was small (Table 3). Using Kaplan-
Meier graphs we also demonstrate the cardiovascular mortality during the study, in the active
Table 2. Levels of C-reactive protein and sP-selectin at study start, after 18 months and at study end in the placebo group, and in the active treat-
ment group.
CRP baseline
(mg/mL)
CRP 18 months
(mg/mL)
CRP 48 months
(mg/mL9
sP-selectin
baseline (ng/ml)
sP-selectin 18
months (ng/mL)
sP-selectin 48
months (ng/mL)
Placebo group,
mean (SD)
4.84 (12.0) 3.69 (3.7) 5.05 (6.2) 56.6 (26.3 57.9 (24.8) 72.3 (35.9)
Active treatment,
mean (SD)
4.06 (11.7) 2.61 (3.2) 2.07 (2.3) 55.9 (22.4) 54.5 (21.1) 58.0 (19.2)
Note: CRP: C-reactive protein.
doi:10.1371/journal.pone.0137680.t002
Fig 2. Graph illustrating C-reactive protein measurements at study start, after 18 months and at study stop at 48 months in the study population
given selenium and coenzymeQ10 combined, or placebo. Note: Analysis according repeated measures of variance.
doi:10.1371/journal.pone.0137680.g002
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treatment and the placebo groups, evaluating the group having CRP or sP-selectin above and
below median levels of the two biomarkers (Figs 4–7).
A significant difference between the active treatment and placebo groups could be demon-
strated in the groups with the inflammation markers below median (CRP: P = 0.021; sP-selec-
tin: P = 0.038), and a weaker evidence, significant at the P<0.1 (CRP: P = 0.053; sP-selectin;
P = 0.054) was found in the groups with above median concentration of the biomarker.
Discussion
In the present study, the dietary supplementation with selenium and coenzyme Q10 combined
reduced the inflammatory response in elderly humans, as judged from measurements of CRP
and the soluble part of sP-selectin.
Fig 3. Graph illustrating sP-selectin measurements at study start, after 18 months and at study stop at 48 months in the study population given
selenium and coenzymeQ10 combined, or placebo.Note: Analysis according repeated measures of variance.
doi:10.1371/journal.pone.0137680.g003
Table 3. Distribution of cardiovascular mortality in placebo and active treatment groups above and belowmedian value of C-reactive protein, and
sP-selectin in the study population during 5 years of follow-up.
CRP > median value CRP < median value sP-selectin > median value sP-selectin < median value
Active treatment 8/103 5/113 8/104 5/112
Placebo 15/108 13/113 16/111 12/110
doi:10.1371/journal.pone.0137680.t003
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We have previously reported an increase of sP-selectin in elderly community inhabitants as
the participants became older [35], and this could be verified in the present study. Interestingly,
the mean concentrations of sP-selectin as well as of CRP decreased during the intervention
with selenium and coenzyme Q10 (Table 2), compared to the placebo group. We also per-
formed evaluations using repeated measures of variance and thereby observed a significant dif-
ference between the active treatment, and the placebo groups, with lowered inflammatory
biomarkers in the actively treated individuals. In the placebo group a small increase in both
Fig 4. Distribution of cardiovascular mortality among those with a C-reactive protein concentration belowmedian in those who received active
supplementation of selenium and coenzymeQ10 combined versus placebo during follow-up of 5.2 years.
doi:10.1371/journal.pone.0137680.g004
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CRP and sP-selectin could be seen, which might reflect an age-related increase in the athero-
sclerosis process. However, the combined intervention appeared to protect against cardiovas-
cular mortality irrespective of the increase in the inflammatory biomarkers (Table 3). Kaplan-
Meier analyses of cardiovascular mortality were made separately for sP-selectin and CRP, each
divided in two at their median value, a protective effect of active intervention with selenium
and coenzyme Q10 could be revealed in both groups, although this was of marginal signifi-
cance in those with the higher inflammatory response.
Fig 5. Distribution of cardiovascular mortality among those with a C-reactive protein concentration abovemedian in those who received active
supplementation of selenium and coenzymeQ10 combined versus placebo during follow-up of 5.2 years.
doi:10.1371/journal.pone.0137680.g005
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The mechanisms behind the effect of intervention with selenium and coenzyme Q10 com-
bined, could be a result of several reactions:
It should be noted that the mean serum selenium concentration in the trial participants at
baseline was low, viz. only about 67 μg/L [36]. The activity of the protective extracellular sele-
noprotein P does not plateau until a serum selenium concentration of about 120 μg/L is
reached[37], and platelet GPX requires comparable selenium levels to be optimized [38].
Thus, selenoproteins that reduce oxidative stress and inflammation and thereby protect endo-
thelial cells may operate sub-optimally in this un-supplemented elderly population, whereas
Fig 6. Distribution of cardiovascular mortality among those with a sP-selectin concentration belowmedian in those who received active
supplementation of selenium and coenzymeQ10 combined versus placebo during follow-up of 5.2 years.
doi:10.1371/journal.pone.0137680.g006
sP-selectin and CRP Reduced by Selenium and CoenzymeQ10
PLOSONE | DOI:10.1371/journal.pone.0137680 September 16, 2015 11 / 16
supplementation may have raised and optimized platelet GPX and extracellular selenoprotein
P in the majority of treated individuals.
Previous studies in comparable groups have shown that selenium supplementation
decreased NF-κB activation and down-regulated the expression of inflammatory genes
[39, 40].
Fig 7. Distribution of cardiovascular mortality among those with a sP-selectin concentration abovemedian in those who received active
supplementation of selenium and coenzymeQ10 combined versus placebo followed during 5.2 years.
doi:10.1371/journal.pone.0137680.g007
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The two selenoproteins GPX and thioredoxin reductase have been shown to protect endo-
thelial cells from oxidants including oxidised LDL [41, 42]. In addition, selenoprotein P, which
is recruited to the endothelial cells in areas of inflammation, scavenges inflammatory agents
and shields endothelial membranes [43, 44]. Furthermore, another selenoprotein, selenopro-
tein S, plays a key role in the control of the inflammatory response [45]. Thus, a decreased
inflammatory response may result from selenium supplementation alone. However, we con-
sider it to be plausible that the observed anti-inflammatory effect results from a synergistic
action of selenium and coenzyme Q10[11, 27]. Also, in an interventional study administering
coenzyme Q10 to forty-three patients with coronary artery disease, Lee et al. reported signs of
reduced oxidative stress as seen by decreased levels of malondialdehyde by 28% [46]. The cor-
relations between CRP and sP-selectin in our groups were low or insignificant: for the placebo
group the correlation was .27 (P = .007) and for the treatment group it was insignificant (r =
.03). This indicates that the common variance was seven percent in the placebo group, and in
the treatment group CRP and sP-selectin responses were independent. Accordingly, the differ-
ent anti-inflammatory processes reflected by the two biomarkers were independent or differen-
tiated in the treated group. Correspondingly, activation of platelets and inflammation form
different parts of the atherothrombotic process, and the different parts may not have been syn-
chronized in the treated group. However, our analyses suggest that intervention with selenium
and coenzyme Q10 is effective, irrespective of the size of the inflammatory responses in the
present elderly population with suboptimal selenium status.
The selenium intake among Europeans in general is low, as a result of low selenium content
in the European soil, resulting in suboptimal levels for at least two of the major selenium con-
taining enzymes, platelet glutathione peroxidase, and selenoprotein P [20]. Moreover, as the
endogenous production of coenzyme Q10 declines after the age of 20, and at the age of 80 [47],
only half of the coenzyme Q10 production can be found in the heart, a benefit from supple-
mentation could be that it restores the intracellular antioxidant and anti-inflammatory poten-
tial. Thus, the effects on CRP and sPs-selectin could be a combined result of optimised
selenium-containing enzymes [14, 48–50], combined with a restoration of decreased coenzyme
Q10 levels. The positive results of our intervention in this minor cohort may be of importance
for large-scale interventions on public health in Europe.
It is therefore important to stimulate further research in the area in order to expand our
knowledge regarding the possibilities to interact in the process of antioxidative defence and
inflammation.
Limitations
The study has a limited size, which is why some statistical evaluations are not meaningful,
which restricts the information of this report. Also, the age span of the included participants
was restricted to elderly persons, which makes extrapolations into other age groups difficult.
However, we argue that the report should be regarded as a hypothesis-generating study, and as
such it has interesting information that could be used in further research.
Conclusions
In this study, blood samples from more than 440 elderly community inhabitants in an inter-
vention study using selenium and coenzyme Q10 combined as a dietary supplement were evalu-
ated regarding the biomarkers C-reactive protein, and sP-selectin, which are markers for
inflammation and atherosclerosis. It could be shown that in those treated with active supple-
mentation, a significant reduction of both CRP and sP-selectin occurred compared to those
receiving placebo over an intervention period of four years. The mechanism behind this effect
sP-selectin and CRP Reduced by Selenium and CoenzymeQ10
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is probably the anti-oxidative effects of both selenium and coenzyme Q10. As previously
reported, reduced cardiovascular mortality has been demonstrated, which is probably associ-
ated with the decreased oxidative state in those receiving active supplementation. However,
this is a small study, and further research is needed to shade light on the mechanisms.
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